Development Challenges
In PrEP drug development, unlike HIV treatment, there is no biomarker of drug effect in susceptible uninfected individuals to inform PrEP trial design. Animal models of HIV challenge have been useful, providing proof of principle, but are limited to non-HIV viruses or by anatomic and pharmacologic differences with humans. Ex vivo HIV challenge of colon tissue biopsy explants from healthy individuals on TFV demonstrates a concentration response and surmounts several animal model limitations (Anton, et al., 2012) . However, the traumatic biopsy and in vitro challenge conditions may introduce influential but clinically irrelevant variables. Explant utility awaits validation against seroconversion events in clinical studies.
Even capturing PK-PD data in RCTs with repeated PK sampling or tissue biopsy is logistically difficult. As a result, sexual mucosal tissue, arguably the critical site of infection and PrEP drug action, has not been studied during any phase 2B/3 RCT. Nonetheless, all of the PrEP RCTs to date have used sparse sampling of plasma, peripheral blood mononuclear cells (PBMCs), or cervicovaginal fluid to measure drug concentrations for correlation with HIV seroconversion. Surprisingly, these accessible nontissue sites yield useful data to guide PrEP dosing and RCT planning.
Explanatory Concentrations
All PrEP RCTs that demonstrated efficacy also showed better efficacy with higher drug concentration. In iPrEx (daily TFV disoproxil fumarate [TDF]/emtricitabine [FTC] in men who have sex with men [MSM]), HIV protection increased from 42% in all participants to 92% in participants with measurable (above assay quantitative limits) plasma TFV (Grant, et al., 2010) . In the Partners in Prevention (PIP) trial (HIV-discordant heterosexual partners on daily TDF or TDF/FTC), the protection increased from 67% to 86% in the TDF arm and 75% to 90% in the TFV/ FTC arm when plasma TFV was measurable (Baeten, et al., 2012) . In CDC TDF2 (daily TDF/FTC in heterosexual women and men), only 50% of seroconverters had measurable plasma TFV compared to >80% of nonseroconverters (Thigpen, et al., 2012) . The Thai injection drug user (IDU) study (daily TDF/FTC) reported a 70% risk reduction in participants with measurable compared to immeasurable plasma TFV (Choopanya, et al., 2013) . By contrast, in FEM-PrEP and VOICE (daily oral TDF or TDF/FTC in heterosexual women), there was no efficacy and no plasma TFV concentration response.
Beyond plasma, CAPRISA 004 investigators showed that women with >1,000 ng/ml cervicovaginal fluid TFV concentration were protected from HIV infection (incidence rate ratio 0.26 compared to placebo), and women below 1,000 ng/ml were not protected (incidence rate ratio 0.86; Karim, et al., 2011) . iPrEx investigators reported 16 fmol/millions cells as the TFV diphosphate (TFV-DP) PBMC concentration associated with 90% protection (Anderson, et al., 2012) . TFV-DP is the active moiety of TFV phosphorylated intracellularly. For this 90% protective concentration to be used as a ''target,'' a confirmatory study would be welcomed. Also, the target may not be relevant for heterosexual men and women whose primary site of infection is not the colon (see below).
There is also concentration response among the TFV-containing PrEP trials (Figure 1 ). The most efficacious trials fall short of complete protection, but higher median RCT plasma concentrations-achievable with consistent daily TDF-likely would achieve greater efficacy. To optimize PrEP efficacy for an individual or in a clinical trial setting, understanding the sources of drug concentration variation in relation to seroconversion is crucial.
Assessing Adherence
The range of median plasma concentrations among oral TFV RCTs is 70 ng/ml to undetectable (<0.3 ng/ml)-a very large 2.4 log 10 difference. Some variation is due to participants taking their doses at different times of day, resulting in variable time between the last scheduled daily dose and the clinic TFV blood collection. However, the expected within-day fluctuations at steady state on daily oral TFV range from 300 ng/ml peak concentrations to 60 ng/ml trough concentrations in plasma-only a 0.7 log 10 difference, explaining little of the observed TFV variation among trials.
Absent evidence of a PK rationale for large inter-and intrastudy concentration difference and the large difference from expectations, poor and variable adherence becomes the best explanation. In a study of daily TFV in South African, Ugandan, and US women, there were no PK differences after an observed dose among racial or geographic subgroups . However, there were 5-fold differences between US and African women in predose TFV concentrations, best explained by adherence differences, as there were no PK differences.
The poor adherence suggested by plasma TFV concentrations is in spite of high degrees of self-reported adherence near 90% or more. In FEM-PrEP and VOICE, less than 40% and 30%, respectively, of participants had evidence of recent drug use at study visits based on plasma TFV. In VOICE, 30% of participants took no TDF in the week prior to any given clinic visit based on undetectable plasma TFV. Other sample types with far longer half-lives -PBMC lysates, dried blood spots, and hair-have less variable daily fluctuations and the capacity to reflect drugtaking behavior averaged over weeks or months prior to collection. None of these methods, however, identify short periods of missed doses that likely affect seroconversion in a trial if concurrent with HIV exposure. Electronic monitoring devices that record pill container opening get closer to capturing actual drug-taking events. The combination of drug concentration and electronic monitoring is being analyzed to model patterns of adherence and covariates.
The highest median TFV concentration among all PrEP RCTs, 70 ng/ml in PIP, falls at the low end of expected concentrations, inconsistent with daily dosing on average unless at least 80% of participants took their last dose 24 hr before the clinic visit. If greater numbers took evening doses, thereby increasing expected concentrations in clinic above 70 ng/ml, adherence estimates fall. Low adherence estimates during a trial could trigger adherence interventions or cessation of enrollment at poorly adherent sites rather than jeopardizing the entire study. In clinical practice, low drug concentrations may warrant adherence interventions. Drug concentrations may also prove useful to test the efficacy of adherence interventions.
Route of Dosing Impact
Vaginal and rectal dosing of TFV gel (40 mg TFV per dose) achieves vaginal and rectal tissue homogenate concentrations of TFV-DP more than 130 and 6-10 times greater, respectively, than after oral dosing (300 mg TDF) in crossover dosing studies (Anton, et al., 2012; Hendrix, et al., 2013) . If tissue is most relevant to sexual HIV protection, one would expect topical dosing to outperform oral dosing. That the two RCTs that included vaginal dosing (CAPRISA 004 and VOICE) achieved among the lowest levels of efficacy suggests needed investigation of variables that might set these studies apart, such as coital dosing (CAPRISA 004), local effects of vaginal dosing, and adherence (Abdool Karim, et al., 2010; J. Marrazzo et al., 2013, 20th Conference on Retroviruses and Opportunistic Infections, abstract). Again, this judgment of underperformance assumes that tissue concentration is the relevant site of action and may be used as a pharmacologic frame of reference.
In contrast to tissue concentrations, serum TFV and PBMC TFV-DP concentrations are far greater after oral dosing-56 and 17 times greater, respectively-in cross-over studies (Dumond, et al., 2007; Schwartz, et al., 2011; Patterson, et al., 2011; Hendrix, et al., 2013) . These differences must be taken into account when comparing oral and topical dosing studies, for example, when using plasma concentration to assess adherence. This is the rationale for the upward adjustment of the VOICE gel arm in the figure.
Route of Infection iPrEx efficacy (42% risk reduction) relative to median TFV plasma concentration (10 ng/ml) does not fall neatly within the concentration response among heterosexual and IDU populations studied despite similar daily TDF (±FTC) regimens (Figure 1) . Two potential differences in MSM may explain this. First, colon has >120 times the vaginal concentrations of tissue homogenate TFV-DP (Patterson, et al., 2011; Louissaint, et al., 2013) . If tissue is the site of drug action, this effectively shifts the concentration upward. Second, the 20-fold or more increased risk of infection from unprotected receptive anal sex compared to receptive vaginal intercourse effectively moves the concentration, partly, back down. This adjustment assumes that higher infection risk is related to greater viral access to susceptible cells that, therefore, require greater drug concentration to maintain protective drug-virus ratios. This upward adjustment brings iPrEx in line with the concentration response relationship of the other risk groups (Figure 1 ). This colon advantage, however, disappears 1 week later in single-dose studies because of colon-vaginal differences in TFV-DP half-life (Patterson, et al., 2011; Louissaint, et al., 2013) , which suggests proportional loss of the benefit with less than daily dosing.
Based on samples of rectal fluid after vaginal dosing and cervicovaginal fluid after rectal dosing, direct TFV diffusion between these two compartments has been observed (Anton, et al., 2012; Hendrix, et al., 2013) . Whether concentrations in the second compartment without the topical dose are protective awaits ongoing biopsy studies and clarification of protective concentrations in each tissue.
The figure naively lumps heterosexual men and women, as PrEP was equally effective in men and women in PIP. Also, there are insignificant male-female differences in TFV plasma PK after oral dosing. Unfortunately, without penile or foreskin PK data in men, one cannot know if potential male-female tissue concentration differences might balance known differences in transmission risk.
Efficacy and TFV concentrations in the Thai IDU study fall slightly below (with largely overlapping distributions) the mixed gender heterosexual studies (PIP, TDF2). CD4+ T cell TFV-DP concentration in PBMCs fall between concentrations from cells extracted from colon and vaginal tissue (Louissaint, et al., 2013) . The agreement in protection and susceptible target cell concentration between heterosexual and IDU populations is a bit surprising. Given greater viral inoculum, founder virus number, and frequency of transmission per exposure with bloodborne IDU infection, one might have anticipated the effective drug concentration to be higher.
Dose Schedule
Except for coitally-dependent dosing prescribed in CAPRISA 004, all of the PrEP RCTs prescribed daily dosing. No study directly compared seroconversion between different dose frequencies. Because CAPRISA 004 differed from other studies in both schedule and route of dosing, it is difficult to link CAPRISA 004 outcomes to other RCTs using plasma concentrations, and it is excluded from the figure. Expected plasma concentrations are lower with vaginal dosing, as discussed above. The highly variable and potentially long period between sex-related gel dosing and clinic blood collections introduces substantial variation and reduction, respectively, in plasma TFV concentration. More study is needed to understand why CAPRISA 004 protection is so far below expectations that are based on high vaginal tissue concentrations with topical compared to oral dosing.
Tentative Targets
One might reduce costs and improve adherence by using PrEP only during periods of high-risk sexual activity. Because TFV phosphorylation takes time, the timing of doses before and after the HIV risk period becomes critical. The iPrEx PBMC TFV-DP 90% efficacious concentration (16 fmol/million cryopreserved cells, 24-48 fmol/million freshly lysed cells) might be a target for episodic PrEP in MSM. In healthy volunteers receiving TDF, PBMC TFV-DP rises gradually, reaches peak 12-24 hr postdose, is sustained for 3-4 days between 10-20 fmol/million freshly lysed cells, and then falls logarithmically with 48 hr half-life (Chen, et al., 2012; Louissaint, et al., 2013) . A single TDF dose cannot reach the 24-48 fmol/million lysed cell target in most men. Doubling the first dose before sexual exposure-per the Anrs Ipergay PrEP trial-increases the chance of hitting the iPrEx target, but only 12-24 hr after dosing. Needed tests of intermittent and episodic PrEP regimens are currently underway.
PD modeling of the typical value from each PrEP trial (except CAPRISA) crudely estimates the median plasma TFV concentration associated with 90% protection (EC 90 ) at 105-110 ng/ml whether using the adjusted plasma concentrations for VOICE gel and iPrEx or excluding each of them. Because prior dose time is unobserved and varies in time relative to plasma TFV sampling, expression of this concentration in adherence terms is complex. Under most scenarios, the EC 90 is achievable only with daily adherence on average. By comparison, the EC 90 in iPrEx was associated with only two to four average doses per week (16 fmol/million cryopreserved PBMC TFV-DP, 10 ng/ml plasma TFV). Pharmacometric modeling with covariates using all data from these RCTs, not just typical values, is greatly needed before acting on very tentative estimates.
The additive effect of FTC is unclear, and there are not as many multicompartment PK studies as for TFV. No efficacy differences appear in RCTs comparing TDF and TDF/FTC arms, but the studies were not powered to pick up modest differences. In addition to variables discussed above, numerous other variables may influence PrEP outcomes: partner viral load, HIV exposure frequency, toxic mucosal effects of topical gel (drug or vehicle) or lubricants, or concomitant sexually transmitted infections. The quantitative impact of these variables is either unknown or difficult to objectively measure in an RCT.
Improving RCT Design
The financial and personnel investment in a PrEP trial is too great to initiate without the use of the best data at hand. Clinical trial simulation (CTS) allows trial planners to explore the sensitivity of various trial designs to influential variables and to compete designs against each other to select optimal designs. CTS for PrEP requires quantitative models of adherence, pharmacokinetics, pharmacodynamics, and HIV transmission dynamics. Intercompartmental PK models and PK-PD linkage models have not been developed aside from iPrEx, but very rich data sets exist to build them. Cautious use of animal models and explant challenge studies may also be helpful. Models describing participant and study characteristics influencing adherence patterns are critical to CTS, given the large impact of adherence on PrEP efficacy. Adherence models can draw upon data from studies with electronic monitoring systems or pre-/postdose PK sampling using population PK models, but these data are less plentifully collected during PrEP trials. Viral dynamic models have been developed based on in vitro and HIV treatment studies and then linked to TFV PK data (from treated populations) to perform simulations of PrEP efficacy and its sensitivity to many of the variables discussed above-target concentration, adherence, time to protective concentrations, and viral inoculums (Duwal, et al., 2012 )-many of which have been confirmed as influential in clinical studies. One key difference is the EC 90 , which is >267 fmol/million fresh lysed cells in the in silico model and 24-48 fmol/million fresh lysed cells in iPrEx (Duwal, et al., 2012; Anderson, et al., 2012) . Far more clinical data from PrEP RCTs and healthy volunteer PK studies are also now available to recalibrate parameter estimates in both in silico and clinical models.
Next-Generation PrEP
Combining sparse PK data from heterogeneous PrEP RCTs with data from more intensely sampled PK studies enables explanation of PrEP outcomes in a more mechanistic manner, enhances our ability to modify regimens to achieve desired concentration targets, and provides many of the elements for CTS. As several new antiretroviral PrEP candidates enter development, the challenge will be to translate the maturing TFV/FTC knowledge to other PrEP candidates, to do so earlier in development, and to better understand nonpharmacological variables so that our attempts to explain, predict, and optimize PrEP will greatly improve with the next generation.
